NCT03256552 - Study to Assess the Efficacy and Safety of Three Doses of PT001 in Japanese Subjects With Moderate to Severe COPD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 28, 2015

Primary Completion Date

September 5, 2015

Study Completion Date

September 5, 2015

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

Glycopyrronium MDI 28.8 micrograms

DRUG

Glycopyrronium MDI 14.4 micrograms

DRUG

Glycopyrronium MDI 7.2 micrograms

DRUG

Placebo MDI

Placebo Inhalation Aerosol

Trial Locations (18)

Pearl Investigative Site, Fukuoka

Pearl Investigative Site, Iizuka-shi

Pearl Investigative Site, Mizunami-shi

Pearl Investigative Site, Sapporo

Pearl Investigative Site, Ako-shi

Pearl Investigative Site, Himeji-shi

Pearl Investigative Site, Kakogawa-shi

Pearl Investigative Site, Kobe

Pearl Investigative Site, Nishinomiya-shi

Pearl Investigative Site, Naka-gun

Pearl Investigative Site, Kawasaki-shi

Pearl Investigative Site, Kyoto

Pearl Investigative Site, Kasaoka-shi

Pearl Investigative Site, Kishiwada-shi

Pearl Investigative Site, Osaka

Pearl Investigative Site, Hamamatsu

Pearl Investigative Site, Chūōku

Pearl Investigative Site, Toshima-ku